Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Varicella zoster vaccine (live/attenuated) | The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Peramivir. |
| Rubella virus vaccine | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Peramivir. |
| Bacillus calmette-guerin substrain tice live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Peramivir. |
| Bacillus calmette-guerin substrain connaught live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Peramivir. |
| Yellow fever vaccine | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Peramivir. |
| Anthrax vaccine | The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Peramivir. |
| Typhoid Vaccine Live | The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Peramivir. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Peramivir. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Peramivir. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Peramivir. |
| Adenovirus type 7 vaccine live | The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Peramivir. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Peramivir. |
| Chikungunya vaccine (live, attenuated) | The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Peramivir. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Peramivir. |